News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
785,231 Results
Type
Article (55720)
Company Profile (354)
Press Release (729141)
Multimedia
Podcasts (143)
Webinars (24)
Section
Business (218686)
Career Advice (2901)
Deals (37838)
Drug Delivery (146)
Drug Development (87157)
Employer Resources (186)
FDA (17587)
Job Trends (16227)
News (372223)
Policy (36332)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2934)
Academic (1)
Accelerated approval (39)
Adcomms (35)
Allergies (166)
Alliances (53631)
ALS (193)
Alzheimer's disease (1802)
Antibody-drug conjugate (ADC) (369)
Approvals (17802)
Artificial intelligence (616)
Autoimmune disease (196)
Automation (46)
Bankruptcy (389)
Best Places to Work (12220)
BIOSECURE Act (21)
Biosimilars (207)
Biotechnology (213)
Bladder cancer (175)
Brain cancer (67)
Breast cancer (691)
Cancer (5298)
Cardiovascular disease (464)
Career advice (2461)
Career pathing (43)
CAR-T (309)
CDC (62)
Celiac Disease (2)
Cell therapy (827)
Cervical cancer (40)
Clinical research (74309)
Collaboration (1923)
Company closure (4)
Compensation (1239)
Complete response letters (80)
COVID-19 (2943)
CRISPR (108)
C-suite (977)
Cystic fibrosis (152)
Data (6730)
Decentralized trials (2)
Denatured (40)
Depression (163)
Diabetes (541)
Diagnostics (7143)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (291)
Drug pricing (222)
Drug shortages (33)
Duchenne muscular dystrophy (265)
Earnings (93749)
Editorial (69)
Employer branding (23)
Employer resources (164)
Events (126038)
Executive appointments (1072)
FDA (20925)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (25)
Funding (1603)
Gene editing (226)
Generative AI (52)
Gene therapy (691)
GLP-1 (1124)
Government (5209)
Grass and pollen (8)
Guidances (388)
Healthcare (20214)
HIV (73)
Huntington's disease (55)
IgA nephropathy (90)
Immunology and inflammation (299)
Immuno-oncology (74)
Indications (137)
Infectious disease (3254)
Inflammatory bowel disease (215)
Inflation Reduction Act (15)
Influenza (130)
Intellectual property (267)
Interviews (559)
IPO (17254)
IRA (59)
Job creations (4350)
Job search strategy (2001)
JPM (70)
Kidney cancer (20)
Labor market (90)
Layoffs (629)
Leadership (44)
Legal (9022)
Liver cancer (102)
Longevity (21)
Lung cancer (711)
Lymphoma (396)
Machine learning (48)
Management (64)
Manufacturing (894)
MASH (185)
Medical device (14476)
Medtech (14542)
Mergers & acquisitions (21700)
Metabolic disorders (1441)
mRNA (192)
Multiple sclerosis (180)
NASH (23)
Neurodegenerative disease (377)
Neuropsychiatric disorders (107)
Neuroscience (3211)
Neurotech (1)
NextGen: Class of 2026 (7167)
Non-profit (4935)
Now hiring (69)
Obesity (697)
Opinion (332)
Ovarian cancer (175)
Pain (234)
Pancreatic cancer (253)
Parkinson's disease (317)
Partnered (34)
Patents (544)
Patient recruitment (559)
Peanut (65)
People (64416)
Pharmaceutical (91)
Pharmacy benefit managers (32)
Phase 1 (23049)
Phase 2 (32538)
Phase 3 (24414)
Pipeline (6271)
Policy (346)
Postmarket research (2972)
Preclinical (9860)
Press Release (71)
Prostate cancer (271)
Psychedelics (60)
Radiopharmaceuticals (307)
Rare diseases (1008)
Real estate (6631)
Recruiting (77)
Regulatory (27063)
Reports (54)
Research institute (2656)
Resumes & cover letters (458)
Rett syndrome (31)
RNA editing (18)
RSV (87)
Schizophrenia (165)
Series A (272)
Series B (201)
Service/supplier (13)
Sickle cell disease (109)
Special edition (27)
Spinal muscular atrophy (172)
Sponsored (45)
Startups (3971)
State (2)
Stomach cancer (21)
Supply chain (119)
Tariffs (99)
The Weekly (101)
Vaccines (1144)
Venture capital (99)
Weight loss (464)
Women's health (104)
Worklife (22)
Date
Today (164)
Last 7 days (691)
Last 30 days (3074)
Last 365 days (31418)
2026 (6028)
2025 (31644)
2024 (36820)
2023 (41747)
2022 (52983)
2021 (57654)
2020 (56522)
2019 (49805)
2018 (37729)
2017 (34733)
2016 (34701)
2015 (40733)
2014 (34842)
2013 (30212)
2012 (32199)
2011 (32811)
2010 (31015)
Location
Africa (965)
Alabama (89)
Alaska (7)
Arizona (334)
Arkansas (15)
Asia (45476)
Australia (8025)
California (12043)
Canada (3454)
China (1221)
Colorado (504)
Connecticut (514)
Delaware (357)
Europe (100215)
Florida (1796)
Georgia (385)
Hawaii (3)
Idaho (65)
Illinois (974)
India (78)
Indiana (559)
Iowa (23)
Japan (468)
Kansas (130)
Kentucky (45)
Louisiana (34)
Maine (73)
Maryland (1481)
Massachusetts (8716)
Michigan (349)
Minnesota (676)
Mississippi (7)
Missouri (144)
Montana (35)
Nebraska (29)
Nevada (132)
New Hampshire (85)
New Jersey (3202)
New Mexico (31)
New York (3176)
North Carolina (1616)
North Dakota (9)
Northern California (5910)
Ohio (358)
Oklahoma (22)
Oregon (47)
Pennsylvania (2425)
Puerto Rico (25)
Rhode Island (51)
South America (1342)
South Carolina (70)
South Dakota (1)
Southern California (4698)
Tennessee (194)
Texas (1870)
United States (42977)
Utah (363)
Vermont (1)
Virginia (298)
Washington D.C. (86)
Washington State (987)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
785,231 Results for "casi pharmaceuticals formerly known as entremed inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
February 25, 2026
·
3 min read
Press Releases
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
December 24, 2025
·
6 min read
Press Releases
CASI Pharmaceuticals Announces Changes in Board Governance
November 20, 2025
·
7 min read
Press Releases
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
December 12, 2025
·
7 min read
Press Releases
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
November 5, 2025
·
1 min read
Press Releases
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
December 9, 2025
·
8 min read
Press Releases
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
November 17, 2025
·
12 min read
Press Releases
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 13, 2026
·
9 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
·
7 min read
Press Releases
CASI Pharmaceuticals Appoints James Huang to Board of Directors
September 29, 2025
·
7 min read
1 of 78,524
Next
